AVITA Medical Management
Management criteria checks 1/4
AVITA Medical's CEO is Jim Corbett, appointed in Sep 2022, has a tenure of 2.25 years. total yearly compensation is $2.07M, comprised of 30.2% salary and 69.8% bonuses, including company stock and options. directly owns 0.033% of the company’s shares, worth €112.42K. The average tenure of the management team and the board of directors is 1.8 years and 6.2 years respectively.
Key information
Jim Corbett
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 30.2% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.8yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$57m |
| Jun 30 2024 | n/a | n/a | -US$50m |
| Mar 31 2024 | n/a | n/a | -US$45m |
| Dec 31 2023 | US$2m | US$625k | -US$35m |
| Sep 30 2023 | n/a | n/a | -US$34m |
| Jun 30 2023 | n/a | n/a | -US$31m |
| Mar 31 2023 | n/a | n/a | -US$26m |
| Dec 31 2022 | US$2m | US$157k | -US$27m |
| Sep 30 2022 | n/a | n/a | -US$30m |
| Jun 30 2022 | n/a | n/a | -US$30m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | US$256k | n/a | -US$25m |
Compensation vs Market: Jim's total compensation ($USD2.07M) is above average for companies of similar size in the German market ($USD1.01M).
Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.
CEO
Jim Corbett (66 yo)
2.3yrs
Tenure
US$2,068,675
Compensation
Mr. James M. Corbett, also known as Jim, served as Chief Executive Officer of CathWorks Ltd. since October 27, 2017 until 2021. He serves as Director of CathWorks Ltd.until 2021. He served as an Independe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 2.3yrs | US$2.07m | 0.033% € 112.4k | |
| Chief Financial Officer | 1.5yrs | US$2.18m | no data | |
| Senior Vice President of Global Operations | 1.8yrs | no data | no data | |
| Senior Vice President of Scientific & Medical Affairs | less than a year | no data | no data | |
| Investor Relations Executive | no data | no data | no data | |
| Chief Legal & Compliance Officer and Corporate Secretary | less than a year | no data | no data | |
| Senior Vice President of Global Marketing & Strategy | 6.4yrs | no data | no data | |
| Senior Vice President of Human Resources | 1.8yrs | no data | no data | |
| Senior Vice President of Product Development & Program Management | 1.8yrs | no data | no data | |
| Senior Vice President of Quality Assurance & Regulatory Affairs | 1.8yrs | no data | no data | |
| Senior Vice President of U.S. Commercial Sales | less than a year | no data | no data |
1.8yrs
Average Tenure
Experienced Management: 51KA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 3.4yrs | US$2.07m | 0.033% € 112.4k | |
| Independent Non-Executive Director | 3.4yrs | US$211.12k | 0.11% € 373.9k | |
| Independent Non-Executive Director | 12.2yrs | US$199.87k | 0.079% € 266.7k | |
| Founder and Member of Clinical Advisory Board | 8.9yrs | US$29.80k | no data | |
| Independent Non-Executive Chairman | 10.4yrs | US$234.69k | 0.16% € 558.7k | |
| Independent Non-Executive Director | 1.7yrs | US$369.11k | 0.075% € 254.0k | |
| Independent Non-Executive Director | 1.7yrs | US$364.94k | 0.037% € 124.6k | |
| Independent Non-Executive Director | 8.9yrs | US$195.28k | 0.10% € 352.3k |
6.2yrs
Average Tenure
67yo
Average Age
Experienced Board: 51KA's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 14:15 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AVITA Medical, Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Lyanne Harrison | BofA Global Research |
| Laura McGuigan | B. Riley Securities, Inc. |